Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

33.17 +0.43 (+1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,629,530
Open 32.89
Bid (Size) 32.98 (2)
Ask (Size) 33.41 (1)
Prev. Close 32.74
Today's Range 32.46 - 33.19
52wk Range 32.02 - 44.66
Shares Outstanding 388,132,400
Dividend Yield 1.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 129 stocks made new 52-week lows. 
Via Benzinga
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga

Performance

YTD
-15.81%
-15.81%
1 Month
-5.39%
-5.39%
3 Month
-6.06%
-6.06%
6 Month
-24.68%
-24.68%
1 Year
-18.48%
-18.48%

More News

Read More
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Earnings Outlook For Royalty Pharma
Via Benzinga
Preview: Royalty Pharma's Earnings
Via Benzinga
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Ominous Death Cross Forms On Royalty Pharma's Chart
Via Benzinga
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
Royalty Pharma Raises Full Year 2023 Guidance
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Insiders Selling TransMedics Group And 2 Other Stocks
Via Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
Via Benzinga
Royalty Pharma Reports Q4 and Full Year 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Five Best And Worst Performing Healthcare Stocks In December 2022
Via Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.